Approaches to discontinuing efalizumab: An open-label study of therapies for managing inflammatory recurrence

BMC Dermatology

Volumn 6, Issue , 2006, Pages

  Papp, Kim A ^a,d   Toth, Darryl ^b   Rosoph, Les ^c  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b Probity Medical Research   (Canada)

^c Probity Medical Research   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; METHOTREXATE; RETINOID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATORY DISEASE; MALE; MORPHOLOGY; MULTICENTER STUDY; PHYSICIAN; PREVALENCE; PSORIASIS VULGARIS; RECURRENT DISEASE; SHORT COURSE THERAPY; STANDARDIZATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PSORIASIS; RECURRENCE; RETINOIDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33751173884     PISSN: 14715945     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-6-9     Document Type: Article

References (21)

1. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ: The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005, 52(1):23-26.
2. Rapp SR, Feldman SR, Exum ML, Fleischer ABJ, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41(3 Pt 1):401-407.
3. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004, 113(12):1664-1675.
4. Tristani-Firouzi P, Krueger GG: Efficacy and safety of treatment modalities for psoriasis. Cutis 1998, 61(2 Suppl):11-21.
5. Lebwohl M, Ali S: Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001, 45(5):649-61; quiz 662-4.
6. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996, 157(11):4986-4995.
7. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004, 208(4):297-306.
8. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003, 290(23):3073-3080.
9. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New England Journal of Medicine 2003, 349(21):2004-2013.
10. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. Journal of the American Academy of Dermatology 2005, 52(3 Pt 1):425-433.
11. Gaylor ML, Duvic M: Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 2004, 3(1):77-79.
12. Scheinfeld N: Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006, 5(2):197-209.
13. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D: Relapse, rebound, and psoriasis adverse events: an advisory group report. Journal of the American Academy of Dermatology 2006, 54(4 (Suppl 1)):S171-S181.
14. Gordon KB, Tyring SK, Hamilton TK, Toth DP, Miller B, Dummer W: Examining duration of response and rebound during treatment with efalizumab (anti-CDIIa).: 21-26 Narch; San Francisco.; 2003:(P594).
15. Lindgren S, Groth O: Generalized pustular psoriasis. A report on thirteen patients. Acta Derm Venereol 1976, 56(2):139-147.
16. Georgala S, Koumantaki E, Rallis E, Papadavid E: Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy. Br J Dermatol 2000, 142(5):1057-1058.
17. Cacoub P, Artru L, Canesi M, Koeger AC, Camus JP: Life-threatening psoriasis relapse on withdrawal of cyclosporin. Lancet 1988, 2(8604):219-220.
18. Ricardo RR, Rhoa M, Orenberg EK, Li N, Rundle AC, Caro I: Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice. Cutis 2004, 74(3):193-200.
19. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT: The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003, 2(3):260-266.
20. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G: Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005, 141(1):82-84.
21. EMEA: Guideline on clinical investigation of medicinal product indicated for the treatment of psoriasis. [http://www.emea.eu.int/pdfs/human/ewp/ 245402en.pdf].